ArticleFrontiers in bioinformatics2026
Evolutionary dynamics of early and late mutational signatures in metastatic cancer.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cancer genomes accumulate somatic mutations over time, influenced by both intrinsic and extrinsic mutational processes. In metastatic cancer, disseminated tumor cells may acquire additional mutations at metastatic sites, shaped by extrinsic factors distinct from those at the primary tumor. As a result, cancer genomes at metastatic sites may bear mutational signatures originating from both primary and metastatic environments. However, the patterns and relative contributions of mutational signatures specific to metastatic sites remain poorly understood. To investigate this, we analyzed mutational signatures from seven metastatic cancer patients. We observed distinct mutational patterns between early and late mutation profiles within individual patients, where the early and late categories were based on their relative timing during tumor evolution. Early mutations were often dominated by a single mutational signature that accounted for more than half of the total signature burden. These dominant signatures tended to be shared among tumors of the same cancer type, suggesting that early mutations in metastatic cancers may be shaped by a single, highly active mutational process at the primary tumor site. In contrast, late mutations were often more poorly decomposed into distinct mutational signatures, reflecting more complex and diverse compositions. Overall, early mutations tended to preserve clearer signals of their origin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.